miR-145 Inhibits Th9 Cell Differentiation by Suppressing Activation of the PI3K/Akt/mTOR/p70S6K/HIF-1α Pathway in Malignant Ascites from Liver Cancer

References

• Akinyemiju T, Abera S, Ahmed MM, Alam N. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–1691. doi:10.1001/jamaoncol.2017.305528983565
   PubMed Web of Science ®Google Scholar
• Qi YF, Li HJ, Li J, Qi YF. Effect of Liushen Pill on PDGF and VEGF expression in H22 liver cancer ascites transplantation tumor and its related mechanism. World Tradit Chin Med. 2013;8(1):69–71.3.
   Google Scholar
• Wu Y, Bao WG, Ding YH, Wu XY, Zhao DW. Clinical and experimental study of xiaoshui decoction in the treatment of primary liver cancer ascites. Chin J Integr Med. 2005;25(12):1066–1069.
   Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–866. doi:10.1038/nrc199717060945
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Toiyama Y, Goel A. An update on microRNAs as colorectal cancer biomarkers: where are we and what’s next? Expert Rev Mol Diagn. 2014;14(8):1–23. doi:10.1586/14737159.2014.94690724308335
   PubMed Web of Science ®Google Scholar
• Kent OA, Chivukula RR, Mullendore M, et al. Repression of the miR-143/145 cluster by oncogenic ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010;24(24):2754–2759. doi:10.1101/gad.195061021159816
   PubMed Web of Science ®Google Scholar
• Yu Y, Nangia-Makker P, Farhana L, Rajendra SG, Levi E, Majumdar AP. miR-21 and miR-145 cooperation in regulation of colon cancer stem cells. Mol Cancer. 2015;14(1):98. doi:10.1186/s12943-015-0372-725928322
   PubMedGoogle Scholar
• Zhen H, Li J, Lin F. miR-145 expression in hepatic carcinoma and its effects on cell proliferation and invasion of tumor. J Tongji Univ. 2012;2:11.
   Google Scholar
• Chung YW, Bae HS, Song JY, et al. Detection of MicroRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patient. Int J Gynecol Cancer. 2013;23(4):673–679. doi:10.1097/IGC.0b013e31828c166d23542579
   PubMed Web of Science ®Google Scholar
• Duan X, Hu J, Wang Y, et al. MicroRNA-145: a promising biomarker for hepatocellular carcinoma (HCC). Gene. 2014;541(1):67–68. doi:10.1016/j.gene.2014.03.01824630966
   PubMed Web of Science ®Google Scholar
• Noguchi S, Yamada N, Kumazaki M, et al. socs7, a target gene of microRNA-145, regulates interferon-β induction through STAT3 nuclear translocation in bladder cancer cells. Cell Death Dis. 2013;4(2):e482. doi:10.1038/cddis.2013.1123392170
   PubMedGoogle Scholar
• Yang XW, Jiang HX, Huang XL, et al. Role of Th9 cells and Th17 cells in the pathogenesis of malignant ascites. Asian Pac J Trop Biomed. 2015;5(10):806–811. doi:10.1016/j.apjtb.2015.07.013
   Google Scholar
• Bahrami A, Hasanzadeh M, Hassanian SM, Shahidsales S, Avan A. The potential value of the PI3K/Akt/mTOR signaling pathway for assessing prognosis in cervical cancer and as a target for therapy. J Cell Biochem. 2017;118(12):4163–4169. doi:10.1002/jcb.2611828475243
   PubMed Web of Science ®Google Scholar
• Céu C, Sofia P, Luís L, et al. Abnormal protein glycosylation and activated PI3K/Akt/mTOR pathway: role in bladder cancer prognosis and targeted therapeutics. PLoS One. 2015;10(11):e0141253. doi:10.1371/journal.pone.014125326569621
   PubMed Web of Science ®Google Scholar
• Yin T, Wang G, He S, et al. Malignant pleural effusion and ascites induce epithelial-mesenchymal transition and cancer stem-like cell properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) pathway. J Biol Chem. 2011;291(52):26750. doi:10.1074/jbc.M116.753236
   Google Scholar
• Shi JS, Jiang K, Li ZD. MiR-145 ameliorates neuropathic pain via inhibiting inflammatory responses and mTOR signaling pathway by targeting Akt3 in a rat model[. Neurosci Res. 2017;S0168010217303851.
   Web of Science ®Google Scholar
• Zhu XF, Zhu RH. Curcumin suppresses the progression of laryngeal squamous cell carcinoma through the upregulation of miR-145 and inhibition of the PI3K/Akt/mTOR pathway. Onco Targets Ther. 2018;11:3521–3531. doi:10.2147/OTT.S15923629950857
   PubMed Web of Science ®Google Scholar
• Zou C, Qing X, Feng M. miR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle. 2012;11(11):2137–2145. doi:10.4161/cc.2059822592534
   PubMed Web of Science ®Google Scholar
• Wang Y, Bi Y, Chen X, et al. Histone deacetylase SIRT1 negatively regulates the differentiation of interleukin-9-producing CD4+ T cells. Immunity. 2016;44(6):1337–1349. doi:10.1016/j.immuni.2016.05.00927317260
   PubMed Web of Science ®Google Scholar
• Boufraqech M, Zhang L, Jain M, et al. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer. 2014;21(4):517–531. doi:10.1530/ERC-14-007724781864
   PubMed Web of Science ®Google Scholar
• Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol. 2008;131(12):1347–1355. doi:10.1038/ni.1677
   Google Scholar
• Veldhoen M, Uyttenhove C, Snick JV, et al. Transforming growth factor-|beta| ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9|ndash|producing subset. Nat Immunol. 2008;9(12):1341–1346. doi:10.1038/ni.165918931678
   PubMed Web of Science ®Google Scholar
• Zheng H, Yang B, Xu D, et al. Induction of specific T helper-9 cells to inhibit glioma cell growth. Oncotarget. 2017;8(3):4864.28002799
   PubMedGoogle Scholar
• Yong L, Qiang W, Gang X, et al. Th9 cells represent a unique subset of CD4 + T cells endowed with the ability to eradicate advanced tumors. Cancer Cell. 2018;33(6):1048–60.e7. doi:10.1016/j.ccell.2018.05.00429894691
   PubMed Web of Science ®Google Scholar
• Lei RE. Role and Mechanism of Interleukin 9 in Liver Cancer and Its Malignant Peritoneal Effusion. Guangxi Medical University.2018.
   Google Scholar
• Zhang PL, Lei RE, Qin QY, Shi C, Jiang HX. Efficacy of anti-IL-9 antibody in the treatment of liver cancer malignant ascites and its mechanism. Chin J Immunol. 2017;3.
   Google Scholar
• Guo H, Ingolia NT, Weissman JS, Bartel DPJN. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835–840. doi:10.1038/nature0926720703300
   PubMed Web of Science ®Google Scholar
• Zhu E, Wang X, Zheng B, Wang Q, Yin Z. miR-20b suppresses Th17 differentiation and the pathogenesis of experimental autoimmune encephalomyelitis by targeting ROR t and STAT3. J Immunol. 2014;192(12):5599–5609. doi:10.4049/jimmunol.130348824842756
   PubMed Web of Science ®Google Scholar
• Wang J, Zheng SS, Xin N, et al. Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response. J Neuroimmune Pharmacol. 2013;8(5):1287–1302. doi:10.1007/s11481-013-9498-924043548
   PubMed Web of Science ®Google Scholar
• Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1 alpha is essential for myeloid cell-mediated inflammation. Cel. 2003;112(5):645–657. doi:10.1016/S0092-8674(03)00154-5
   PubMed Web of Science ®Google Scholar
• Shi LZ, Wang R, Huang G, Vogel P, Chi H. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med. 2011;208(7):1367–1376. doi:10.1084/jem.2011027821708926
   PubMed Web of Science ®Google Scholar
• Dang EV, Barbi J, Yang H-Y, et al. Control of TH17/Treg balance by hypoxia-inducible factor 1. Cell. 2011;146(5):0–784. doi:10.1016/j.cell.2011.07.033
   Web of Science ®Google Scholar
• Vogel C, Marcotte EMJNRG. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13:679. doi:10.1038/nrg318522945394
   PubMed Web of Science ®Google Scholar